DUBLIN, December 12, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/sd3m2k/global_sexually) has announced the addition of the "Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
A new report titled, "Global Market for Diagnostic Testing of Sexually Transmitted Diseases (STDs) (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020", considers commercial aspects of the diagnostic testing of sexually transmitted diseases.
Based on key trends tracked, it is anticipated that the diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, registering a CAGR of 8.5% during 2014-2020. The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacificand African regions along with complimenting growth rate of the European market.
Sexually transmitted diseases or venereal diseases (VDs) are one of the most critical health challenges facing the world today. Rising rate of incidence of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) are factors that drive the growth of the diagnostic testing market for STDs. Clinical manifestations of STD, for example, Chlamydia range from Urethritis, Epididymitis, Orchitis, Infertility in men to Cervicitis, Endometritis, Salpingitis, PID, infertility and Perihepatitis in women; and untreated STDs that display such manifestations are often fatal.
The risk of transmission of Chlamydia infection from an infected male to a female partner is estimated to be about 40% and from an infected female to male is about 30%. Such high rate of transmission, coupled with high rate of undiagnosed and untreated cases (about 85% of women and 40% of men are asymptomatic), renders huge economic burden on healthcare departments across all countries.
To ameliorate such cases, healthcare departments across the world, have initiated national screening and also incentivized voluntary screening. Overall, the afore-mentioned factors result in high testing volume for Chlamydia, which contributes to a larger market share in terms of value. HIV, is incurable and prognosis of HIV leads to numerous infections that result in fatality. HIV infected patients also suffer from other co-infections; HIV and Syphilis have a high co-infection rate of about 25%. Akin to national and voluntary screening implemented for Chlamydia, many healthcare departments implemented CICT and PICT screening for HIV too. Such screening programs are expected to increase HIV testing volumes, which is estimated to reach 2.1 billion by 2020.
The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.
Key Topics Covered:
1 INTRODUCTION
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
4 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY DISEASE TYPE
5 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY LOCATION OF TESTING
6 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY TESTING DEVICES
7 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY GEOGRAPHY
8 COMPANY PROFILES
Companies Mentioned:
- Abbott Laboratories
- Affymetrix, Inc.
- Alere, Inc.
- Becton Dickinson & Company
- BioMerieux
- Cepheid, Inc.
- Danaher Corporation
- DiaSorin
- Hologic, Inc.
- Roche Diagnostics
For more information visit http://www.researchandmarkets.com/research/sd3m2k/global_sexually
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
